PDA Severity Score Predicting Chronic Lung Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately assess the hemodynamic significance of patent ductus arteriosus (PDA) in preterm infants, leading to ambiguity in determining the need for treatment and potential complications such as intraventricular hemorrhage, chronic lung disease, and mortality, due to the lack of reliable markers for shunt volume and flow dynamics.
Innovation Solution
A method involving echocardiographic measurements and a regression model to determine a PDA severity score, using variables like gestational age, pulmonary perfusion index, left ventricular output, and diastolic flow reversal in the descending aorta, to identify hemodynamically significant PDA and predict the risk of chronic lung disease, allowing for timely pharmacological or surgical intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical signs are used to assess PDA, then the assessment method is simple, but the measurement precision is poor leading to ambiguity in hemodynamic significance
Solution Approach 1:
The patent transforms the assessment from simple clinical observation to a quantitative multi-parameter echocardiographic evaluation system. Six specific echocardiographic parameters (PDA diameter, PDA velocity, LA:Ao ratio, pulmonary artery diameter, descending aorta diameter, and pulmonary vein flow) are measured and combined through a regression model to generate a PDA severity score, converting subjective clinical assessment into objective quantifiable measurement.
Solution Approach 2:
The echocardiographic assessment system serves multiple functions simultaneously: it measures anatomical dimensions (PDA diameter, chamber sizes), evaluates flow dynamics (PDA velocity, pulmonary vein flow), assesses hemodynamic impact (LA:Ao ratio indicating left atrial pressure), and generates a composite severity score that predicts clinical outcomes, replacing multiple separate assessment tools with a single integrated system.
2Reliability
If PDA treatment is initiated based on current methods, then treatment may be provided, but the reliability of treatment necessity determination is low due to lack of reliable shunt volume markers
Solution Approach 1:
The patent introduces echocardiographic parameters as intermediary indicators that indirectly reflect shunt volume and hemodynamic significance. Since direct shunt volume measurement is not feasible, the system uses measurable surrogates (PDA diameter, PDA velocity, LA:Ao ratio, pulmonary artery diameter) that correlate with shunt volume and are combined through a regression model to infer the unmeasurable shunt volume and predict clinical outcomes.
Solution Approach 2:
The regression model provides feedback by generating a PDA severity score that predicts the likelihood of adverse outcomes (chronic lung disease or death). This feedback loop allows clinicians to assess treatment necessity based on predicted risk rather than uncertain clinical signs, with the model continuously refined using outcome data to improve predictive accuracy.
3Object-affected harmful factors
If early treatment is provided to all PDA cases, then potential complications may be reduced, but unnecessary treatments increase due to inability to distinguish hemodynamically significant PDA
Solution Approach 1:
The patent applies local quality by differentiating treatment based on individual PDA severity characteristics rather than uniform treatment of all PDA cases. The PDA severity score identifies specific infants with hemodynamically significant PDA (those at high risk for adverse outcomes) versus those with less significant PDA, allowing targeted treatment to be applied locally to the specific subset of patients who benefit most, reducing unnecessary treatments in low-risk patients.
Data Source
AI summary
The present disclosure is directed to methods of utilizing echocardiography for assessing hemodynamic significance of patent ductus arteriosus (PDA) at early time points to supplement a patient's clinical and laboratory data by determining a PDA severity score. The present disclosure is further directed to treating the patient for PDA based on the severity score.